Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux
Our findings identify novel HER3/CYLD/ABCB1 axis that regulate tumor growth and DDP resistance, which may be used as potential novel therapeutic target(s) to overcome ovarian cancer DDP resistance.
Authors
- Xiaoyu Jia
- Bing‐Hua Jiang (ORCID: https://orcid.org/0000-0003-4526-2031)
- Wenjing Liu (ORCID: https://orcid.org/0000-0001-5081-9047)
- Lin Wang (ORCID: https://orcid.org/0000-0001-7302-6437)
- Xue Wang (ORCID: https://orcid.org/0000-0002-1663-9218)
- Ye Zhang (ORCID: https://orcid.org/0000-0002-3494-7206)
- Jian‐Ge Qiu (ORCID: https://orcid.org/0000-0002-2215-2449)
- Hongbin Ji (ORCID: https://orcid.org/0000-0003-0891-6390)
- Fan-Li Sun
- Wei J. Wang (ORCID: https://orcid.org/0000-0002-4848-7394)
Institutions
- Chinese Academy of Sciences (CN)
- Zhengzhou University (CN)
- Center for Excellence in Molecular Cell Science (CN)
- Henan Cancer Hospital (CN)
Publication Details
- Journal
- Experimental Hematology and Oncology
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1186/s40164-025-00620-z
- Citations
- 5
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 8.49
Funders
- National Natural Science Foundation of China